Chee M Ng

Summary

Affiliation: The Children's Hospital of Philadelphia
Country: USA

Publications

  1. ncbi request reprint Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey
    Chee M Ng
    Clinical Pharmacology and Therapeutic, Children Hospital of Philadelphia, PA, United States School of Medicine, University of Pennsylvania, Philadelphia, PA, United States Electronic address
    Eur J Pharm Sci 51:51-8. 2014
  2. pmc Novel hybrid GPU-CPU implementation of parallelized Monte Carlo parametric expectation maximization estimation method for population pharmacokinetic data analysis
    C M Ng
    Division of Clinical Pharmacology and Therapeutics, Children s Hospital of Philadelphia, CTRB Building Room 4010, 3501 Civic Center Blvd, Philadelphia, Pennsylvania, 19104, USA
    AAPS J 15:1212-21. 2013
  3. doi request reprint Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients
    Chee M Ng
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
    Cancer Chemother Pharmacol 67:985-94. 2011
  4. doi request reprint Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies
    Chia Chi Lin
    The Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 65:167-75. 2009
  5. doi request reprint GPU-accelerated nonparametric kinetic analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab
    Yu Han H Hsu
    Division of Clinical Pharmacology and Therapeutics, The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Magn Reson Imaging 31:618-23. 2013
  6. ncbi request reprint Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function
    Chris H Takimoto
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78245 3217, USA
    Clin Cancer Res 13:4832-9. 2007
  7. doi request reprint Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients
    Chee M Ng
    Cancer Therapy and Research Center, Institute for Drug Development, The University of Texas Health Science Center at San Antonio, San Antonio, 78229, USA
    Cancer Chemother Pharmacol 65:207-17. 2010

Collaborators

Detail Information

Publications7

  1. ncbi request reprint Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey
    Chee M Ng
    Clinical Pharmacology and Therapeutic, Children Hospital of Philadelphia, PA, United States School of Medicine, University of Pennsylvania, Philadelphia, PA, United States Electronic address
    Eur J Pharm Sci 51:51-8. 2014
    ..A semi-mechanistic model was developed to investigate the quantitative relationship between the FcRn binding affinity and PK of mAbs in cynomolgus monkey with the presence of ATA...
  2. pmc Novel hybrid GPU-CPU implementation of parallelized Monte Carlo parametric expectation maximization estimation method for population pharmacokinetic data analysis
    C M Ng
    Division of Clinical Pharmacology and Therapeutics, Children s Hospital of Philadelphia, CTRB Building Room 4010, 3501 Civic Center Blvd, Philadelphia, Pennsylvania, 19104, USA
    AAPS J 15:1212-21. 2013
    ..The novel hybrid GPU-CPU implementation of parallelized MCPEM algorithm developed in this study holds a great promise in serving as the core for the next-generation of modeling software for population PK/PD analysis. ..
  3. doi request reprint Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients
    Chee M Ng
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
    Cancer Chemother Pharmacol 67:985-94. 2011
    ..The objective of this study was to develop a mechanism-based population pharmacokinetic/pharmacodynamic (PK/PD) model in describing troxacitabine-induced neutropenia in patients with cancer...
  4. doi request reprint Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies
    Chia Chi Lin
    The Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 65:167-75. 2009
    ....
  5. doi request reprint GPU-accelerated nonparametric kinetic analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab
    Yu Han H Hsu
    Division of Clinical Pharmacology and Therapeutics, The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Magn Reson Imaging 31:618-23. 2013
    ..This finding indicates that the GPU-based method can significantly shorten the computational times required to assess tumor physiology from DCE-MRI data in preclinical and clinical development of antivascular therapies...
  6. ncbi request reprint Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function
    Chris H Takimoto
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78245 3217, USA
    Clin Cancer Res 13:4832-9. 2007
    ..To characterize the pharmacokinetics and pharmacodynamics of oxaliplatin in cancer patients with impaired renal function...
  7. doi request reprint Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients
    Chee M Ng
    Cancer Therapy and Research Center, Institute for Drug Development, The University of Texas Health Science Center at San Antonio, San Antonio, 78229, USA
    Cancer Chemother Pharmacol 65:207-17. 2010
    ..A mechanism-based pharmacokinetic (PK)/pharmacodynamic (PD) model was developed to investigate the dynamic interaction between volociximab concentrations and free monocyte α(5)β(1) integrin levels in cancer patients...